[1] |
Yang M, Huo X, Miao Z, et al. Platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor tirofiban in acute ischemic stroke[J]. Drugs, 2019, 79(5): 515-529.
|
[2] |
Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke: The SaTIS trial[J]. Stroke, 2011, 42(9): 2388-2392.
doi: 10.1161/STROKEAHA.110.599662
pmid: 21852609
|
[3] |
Huo X, Raynald, Wang A, et al. Safety and efficacy of tirofiban for acute ischemic stroke patients with large artery atherosclerosis stroke etiology undergoing endovascular therapy[J]. Front Neurol, 2021, 12: 630301.
|
[4] |
替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志, 2019, 14(10): 1034-1044.
doi: 10.3969/j.issn.1673-5765.2019.10.013
|
[5] |
Yi YH, Yin WJ, Gu ZC, et al. A simple clinical pre-procedure risk model for predicting thrombocytopenia associated with periprocedural use of tirofiban in patients undergoing percutaneous coronary intervention[J]. Front Pharmacol, 2018, 9: 1456.
doi: 10.3389/fphar.2018.01456
pmid: 30618750
|
[6] |
Konstantinou K, Davies JR, Alsanjari O, et al. Clinical effectiveness of thrombus aspiration during percutaneous coronary intervention for stent thrombosis in a contemporary setting[J]. Hellenic J Cardiol, 2022, 66: 11-18.
|
[7] |
Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein Ⅱb/Ⅲa receptor antagonists[J]. Am J Cardiol, 2006, 97(3): 426-429.
pmid: 16442410
|
[8] |
王刚, 李泽亚, 叶智帅, 等. 替罗非班致极重度血小板减少救治1例并文献复习[J]. 中国医药, 2023, 18(8): 1251-1254.
|
[9] |
Wang J, Zou D. Tirofiban-induced thrombocytopenia[J]. Ann Med, 2023, 55(1): 2233425.
|
[10] |
Bosco A, Kidson-Gerber G, Dunkley S. Delayed tirofiban-induced thrombocytopenia: Two case reports[J]. J Thromb Haemost, 2005, 3(5): 1109-1110.
doi: 10.1111/j.1538-7836.2005.01296.x
pmid: 15869625
|
[11] |
中华医学会血液学分会血栓与止血学组. 弥散性血管内凝血诊断中国专家共识(2017年版)[J]. 中华血液学杂志, 2017, 38(5):361-363.
|
[12] |
中华医学会内科学分会, 王建祥, 张奉春, 等. 中国成人血小板减少症诊疗专家共识[J]. 中华内科杂志, 2020, 59(7):498-510.
|
[13] |
Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPⅡb/Ⅲa[J]. Blood, 2002, 100(6): 2071-2076.
|
[14] |
Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPⅡb/Ⅲa inhibitors: Position paper of the ISTH working group on thrombocytopenia and GPⅡb/Ⅲa inhibitors[J]. J Thromb Haemost. 2006. 4(3): 678-679.
doi: 10.1111/j.1538-7836.2006.01829.x
pmid: 16460451
|
[15] |
Rahman N, Jafary FH. Vanishing platelets: Rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction[J]. Tex Heart Inst J, 2010. 37(1): 109-112.
pmid: 20200641
|
[16] |
Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting[J]. Circulation, 2004, 109(18): 2203-2206.
pmid: 15117843
|
[17] |
Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors[J]. Am Heart J, 1999, 138(4 Pt 2): 317-326.
|
[18] |
中国成人血小板减少症急诊管理共识专家组. 中国成人血小板减少症急诊管理专家共识[J]. 中华急诊医学杂志, 2022, 31(2):161-168.
|
[19] |
Li Y, Qiu J, Gao Y, Li G. Case report: Reuse of tirofiban leads to very severe thrombocytopenia[J]. Front Cardiovasc Med, 2023, 10: 1130552.
|